JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 114 filers reported holding JOUNCE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.78 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $159 | -100.0% | 143,218 | -0.8% | 0.00% | 0.0% |
| Q3 2022 | $338,000 | -22.8% | 144,403 | -0.1% | 0.00% | -50.0% |
| Q2 2022 | $438,000 | -55.5% | 144,575 | -0.2% | 0.00% | -50.0% |
| Q1 2022 | $984,000 | -18.6% | 144,929 | +0.1% | 0.00% | -20.0% |
| Q4 2021 | $1,209,000 | +8.8% | 144,749 | -3.2% | 0.01% | -16.7% |
| Q3 2021 | $1,111,000 | +9.4% | 149,463 | +0.0% | 0.01% | 0.0% |
| Q2 2021 | $1,016,000 | -33.8% | 149,455 | +0.0% | 0.01% | -45.5% |
| Q1 2021 | $1,534,000 | +46.7% | 149,397 | 0.0% | 0.01% | +37.5% |
| Q4 2020 | $1,046,000 | -14.2% | 149,397 | 0.0% | 0.01% | -27.3% |
| Q3 2020 | $1,219,000 | +18.2% | 149,397 | -0.0% | 0.01% | +10.0% |
| Q2 2020 | $1,031,000 | +45.2% | 149,428 | +0.0% | 0.01% | +11.1% |
| Q1 2020 | $710,000 | – | 149,397 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 1,347,829 | $9,152,000 | 93.42% |
| Ally Bridge Group (NY) LLC | 550,000 | $3,735,000 | 2.77% |
| ACUTA CAPITAL PARTNERS, LLC | 813,500 | $5,524,000 | 2.58% |
| TRV GP III, LLC | 1,148,780 | $7,800,000 | 2.12% |
| Deep Track Capital, LP | 4,259,653 | $28,923,000 | 1.86% |
| Logos Global Management LP | 1,400,000 | $9,506,000 | 1.23% |
| PFM Health Sciences, LP | 3,972,868 | $26,976,000 | 1.01% |
| Sofinnova Investments, Inc. | 1,481,219 | $10,057,000 | 0.76% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 248,347 | $1,686,000 | 0.70% |
| RTW INVESTMENTS, LP | 4,680,412 | $31,780,000 | 0.66% |